The 12th CTAD (Clinical Trials on Alzheimers's Disease) congress was held in San Diego (California) from 4 to 7 December 2019. The scientists present were eagerly awaiting Biogen's presentation of the first results of Aducanumab. Aducanumab is believed to slow the progression of the disease in its early stages. Indeed, after the abrupt termination of the clinical trials - in which the Swiss Memory Centres were participating - in March 2019, a more complete analysis of the data showed a reduction in deterioration in patients treated with the highest dose of the drug, in one of the two twin studies conducted in parallel (ENGAGE and EMERGE). In addition, Biogen announced that it is awaiting a response from the Food and Drug Administration (FDA) regarding their application for market approval of the drug.
Dernière mise à jour : 26/11/2020